A Phase 4 interventional study of High Dose Interleukin-2 and Ipilimumab in Metastatic Melanoma, sponsored by Clinigen, Inc.. Terminated at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-05.
Sponsored by Clinigen, Inc. · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing Interleukin-2 in Melanoma — none open to participants now, 2 under way, none of them phase 3. Interleukin-2 · Melanoma.
Among the 43 studies testing Interleukin-2 in Melanoma, this one is the 11th largest by enrollment of the 41 interventional ones that give a count, is one of 3 that started in 2013, is the only one in phase 4, and was the 30th registered.
3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.
Browse Melanoma studies →None of the 43 studies testing Interleukin-2 in Melanoma is open now. The open studies under Melanoma, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 31 · Phase 3 3 · Phase 4 1
First in 1998; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 29 is below the median of 40 across 2,651 interventional studies indexed under Melanoma.
Median enrollment 15 across the 41 interventional studies. Of the 34 that completed or were terminated, 16 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 43 have an industry lead sponsor. The 10 most frequent:
Clinigen, Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.
Clinigen, Inc. has 2 studies filed under Melanoma — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 43 studies testing Interleukin-2 in Melanoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Phase IV, open-label, randomized, two-arm, multi-center study in patients with metastatic melanoma who are treatment naïve or have previously received a single non-immunologic therapy.
Treatment Arm 1: "HD IL-2 first, then ipilimumab" Patients will receive two courses (four cycles) of High Dose Interleukin-2 (HD IL-2) followed by one course (four doses) of ipilimumab.
Treatment Arm 2: Ipilimumab first then HD IL-2 Patients will receive one course (four doses) of ipilimumab followed by two courses (four cycles) of HD IL-2.
All patients will receive IL-2 at 600,000 international units per kilogram (kg) by intravenous bolus (IVB) every 8 hours for up to 14 planned doses with an additional cycle 14 days after the first.
Ipilimumab 3mg/kg IV infusion Q3 weeks up to 4 doses4 doses A 3-6 week interval been the administration of the two drugs to allow for resolution of treatment-related toxicities.
If corticosteroids were required during Ipilimumab administration, a 2-week period from discontinuation of steroid treatment to start of HD IL-2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive two courses (four cycles) of High Dose Interleukin-2 (HD IL-2) followed by one course (four doses) of ipilimumab.
Drug: High Dose Interleukin-2 · Drug: Ipilimumab
Patients will receive one course (four doses) of ipilimumab followed by two courses (four cycles) of HD IL-2.
Drug: High Dose Interleukin-2 · Drug: Ipilimumab
Also known as: Aldesleukin, Proleukin, interleukin
Also known as: Yervoy, anti-CTLA4
Estimated One-year OS in the Evaluable Population in Each Treatment Arm Separately
evaluable patients who received at least 50% of both research drugs and had their disease re-evaluated after baseline; defined in days for the start of the first treatment to death. percent of patients alive at 1 year; estimates were assessed using Kaplan-Meier method for the entire subject population for each treatment arm separately.
Time frame: start of first treatment to date of death from any cause and patients alive at their last evaluation date were censored up to 1 year.
Progression-free Survival
duration of time (in Days) from start of the first treatment to the time of objective disease progression or death at one year. The immune-related response criteria (irRC) determined based on tumor burden calculated on the WHO method of multiplying the perpendicular dimensions of all lesions are summed to obtain the tumor burden. The total tumor burden + SPD (index lesions) + SPD (new measurable lesions) Based on CT scans and Physical exam at designated timepoints. CR- Disappearance of all known disease; PR\>/equal to decrease; SD Neither CR or PD; PD 25%increase; new lesion.
Time frame: 5-11 weeks, 13-19 Weeks, 24-30 weeks and 1 year
Study initiation Sept 11, 2013 - Early Study Termination August 18, 2015 Planned accrual 50 pts/ arm.
| Milestone | Treatment Arm 1 HD IL-2 1st Followed by Ipilimumab | Treatment Arm 2 Ipilimumab 1st Followed by HD IL-2 |
|---|---|---|
| Started | 13 | 16 |
| Intent to treat: received one dose of study drug | 12 | 16 |
| Evaluable: received 50% of each study drug | 8 | 10 |
| Completed | 3 | 4 |
| Not completed | 10 | 12 |
| Withdrew: Death | 1 | 2 |
| Withdrew: Adverse event | 2 | 1 |
| Withdrew: Lack of efficacy | 5 | 5 |
| Withdrew: Non compliance, study closure | 1 | 3 |
| Withdrew: Withdrawal by subject | 1 | 1 |
evaluable patients who received at least 50% of both research drugs and had their disease re-evaluated after baseline; defined in days for the start of the first treatment to death. percent of patients alive at 1 year; estimates were assessed using Kaplan-Meier method for the entire subject population for each treatment arm separately.
| percentage of participants | Treatment Arm 1 | Treatment Arm 2 |
|---|---|---|
| Estimated One-year OS in the Evaluable Population in Each Treatment Arm Separately | 73 (38 to 91) | 75 (40 to 92) |
duration of time (in Days) from start of the first treatment to the time of objective disease progression or death at one year. The immune-related response criteria (irRC) determined based on tumor burden calculated on the WHO method of multiplying the perpendicular dimensions of all lesions are summed to obtain the tumor burden. The total tumor burden + SPD (index lesions) + SPD (new measurable lesions) Based on CT scans and Physical exam at designated timepoints. CR- Disappearance of all known disease; PR\>/equal to decrease; SD Neither CR or PD; PD 25%increase; new lesion.
| days | Treatment Arm 1 HD IL-2 1st Followed by Ipilimumab | Treatment Arm 2 Ipilimumab 1st Followed by HD IL-2 |
|---|---|---|
| Progression-free Survival | 58 (18 to 84) | 80 (41 to 95) |
Collected over Adverse events were monitored/ assessed for up to 30 weeks after 1st dose of study drug. All -cause mortality monitored/assessed up to 1 year.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Arm 1 HD IL-2 Administered 1st Followed by Ipilimumab | 1/13 (7.7%) | 9/13 (69.2%) | 9/13 (69.2%) |
| Treatment Arm 2 Ipilimumab Administered 1st Followed by HD IL-2 | 2/16 (12.5%) | 10/16 (62.5%) | 10/16 (62.5%) |
| Event | Treatment Arm 1 HD IL-2 Administered 1st Followed by Ipilimumab | Treatment Arm 2 Ipilimumab Administered 1st Followed by HD IL-2 |
|---|---|---|
| supraventricular tachycardia, ventricular tachycardiaCardiac disorders | 2/13 | 0/16 |
| Autoimmune encephalitis, intracranial HemorrhageNervous system disorders | 2/13 | 0/16 |
| colitisGastrointestinal disorders | 0/13 | 2/16 |
| PneumoniaInfections and infestations | 0/13 | 2/16 |
| Respiratory Failure, HypoxiaRespiratory, thoracic and mediastinal disorders | 1/13 | 2/16 |
| DiarrheaGastrointestinal disorders | 1/13 | 0/16 |
| back pain, neck painMusculoskeletal and connective tissue disorders | 1/13 | 0/16 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/13 | 0/16 |
| embolismVascular disorders | 1/13 | 0/16 |
| wound infectionInfections and infestations | 1/13 | 0/16 |
| Event | Treatment Arm 1 HD IL-2 Administered 1st Followed by Ipilimumab | Treatment Arm 2 Ipilimumab Administered 1st Followed by HD IL-2 |
|---|---|---|
| Acute Kidney InjuryRenal and urinary disorders | 8/13 | 2/16 |
| diarrheaGastrointestinal disorders | 4/13 | 1/16 |
| Back pain, neck painMusculoskeletal and connective tissue disorders | 4/13 | 0/16 |
| increased creatinineBlood and lymphatic system disorders | 3/13 | 0/16 |
| Muscular WeaknessMusculoskeletal and connective tissue disorders | 3/13 | 0/16 |
| Peripheral EdemaGeneral disorders | 3/13 | 1/16 |
| HypotensionVascular disorders | 3/13 | 1/16 |
| FlushingVascular disorders | 3/13 | 0/16 |
| Increased BUNBlood and lymphatic system disorders | 2/13 | 0/16 |
| NauseaGastrointestinal disorders | 2/13 | 1/16 |
| Age, Categorical(Participants) | Treatment Arm 1 IL-2 First | Treatment Arm 2 Ipi First | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 12 | 14 | 26 |
| >=65 years | 1 | 2 | 3 |
| Age, Continuous(years) | Treatment Arm 1 IL-2 First | Treatment Arm 2 Ipi First | Total |
|---|---|---|---|
| Median | 49.5 (32 to 70) | 46 (20 to 69) | 48 (20 to 70) |
| Sex: Female, Male(Participants) | Treatment Arm 1 IL-2 First | Treatment Arm 2 Ipi First | Total |
|---|---|---|---|
| Female | 5 | 4 | 9 |
| Male | 8 | 12 | 20 |
| Region of Enrollment(participants) | Treatment Arm 1 IL-2 First | Treatment Arm 2 Ipi First | Total |
|---|---|---|---|
| United States | 13 | 16 | 29 |
The record gives a start of May 2013, a primary completion of Jul 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2023, 8 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Interleukin-2 · Ipilimumab
Clinigen, Inc.